drugset / Trial / NCT02059772

Combination of Standard Lucentis Therapy With Micropulse Diode Laser for the Treatment of Diabetic Macular Edema

NCT02059772

Phase 4 Unknown 25 enrolled GWT-TUD GmbH Novartis · collab
RandomizedParallel-groupOpen-labelTreatment

Summary

The primary objective of this study is to evaluate if a combination therapy with micropulse diode laser treatment shows non inferiority on visual acuity within 12 months in comparison to standard therapy (intravitreal injection of ranibizumab only).

Timeline

Start
2014-04-30
Primary completion
2017-11
Completion
2017-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Ranibizumab Monoclonal antibody 0.5 mg Intravitreal